NCT number Condition or disease The device, frequency, intensity, and exposure time of TTFields Combining therapy status
NCT02831959 Non-small cell lung cancer brain metastasis NovoTTF-200A; 150 kHz; >18 hours/day Stereotactic radio surgery Recruiting
NCT05341349 Melanoma brain metastases NovoTTF-100M; ≥8hours/day Ipilimumab, Nivolumab, Pembrolizumab, Stereotactic, Radiosurgery Not yet recruiting
NCT04967027
Brain metastasis with drug/radiation resistant
ASCLU-300 TTF; ≥18hours/day
-
Recruiting
NCT04221503 GBM Optune; ≥18hours/day Niraparib, Planned surgical resection Recruiting
NCT04689087 rGBM Not mentioned  Second-line chemotherapy treatment Recruiting
NCT04223999 First recurrence GBM ≥18hours/day Skullremodeling surgery Recruiting
NCT04397679 ndGBM ≥18hours/day Partial Brain radiotherapy, Temozolomide, Chloroquine Recruiting
NCT03405792 ndGBM Optune; 24months Temozolomide, Pembrolizumab Active, not recruiting
NCT03223103 ndGBM Optune Poly-ICLC, Peptides Active, not recruiting
NCT04671459 GBM and rGBM Optune Stereotactic radiosurgery Recruiting
NCT05030298 Malignant Glioma Not available RT, TMZ, radiosurgery Not yet recruiting
NCT04902586 Glioma and GBM Low-intensity; 200 kHz; ≥18hours/day Radiotherapy Not yet recruiting
NCT04396860 Gliosarcoma and MGMT-unmethylated GBM NovoTTF-100A Ipilimumab, Nivolumab Recruiting
NCT03033992 Paediatric malignant glioma ependymoma NovoTTF-200A; ≥18hours/day - Recruiting
NCT05086497 GBM  Optune array layout mapping created from conventional/advanced MR imaging sequences - Not yet recruiting